Immunotherapies in development for the treatment of non-Hodgkin lymphoma
| Trial | Agents investigated | Agent description | Primary outcome for assessment |
| POLARGO (NCT04182204) | Polatuzumab vedotin-piiq+R-GemOx vs R-GemOx for R/R DLBCL | ADC | Rate of adverse events, OS |
| POLARIX (NCT03274492) | Polatuzumab vedotin-piiq+R-CHP vs R-CHOP for first-line DLBCL | ADC | PFS |
| BELINDA (NCT03570892) | Chemotherapy+tisagenlecleucel vs Chemotherapy+autoSCT for R/R B cell NHL | CAR T cell | EFS |
| TRANSCEND-NHL-001 (NCT02631044) | Lisocabtagene maraleucel | CAR T cell | Treatment-related adverse events, dose-limiting toxicities, ORR |
| TRANSFORM (NCT03575351) | SOC (R-DHAP, R-ICE, or R-GDP; followed by HDCT (BEAM) and stem cell transplant) vs JCAR017 (lisocabtagene maraleucel) for R/R B cell NHL | CAR T cell | EFS |
| ZUMA-5 (NCT03105336) | Axicabtagene ciloleucel+cyclophosphamide+fludarabine for R/R indolent NHL | CAR T cell | ORR |
| ZUMA-7 (NCT03391466) | Axicabtagene ciloleucel vs SOC for R/R DLBCL | CAR T cell | EFS |
| NIVEAU (NCT03366272) | Nivolumab+R-GemOx vs R-GemOx for R/R B cell NHL | ICI | PFS |
| NCT03016000 | Thalidomide maintenance for DLBCL | IMiD | Relapse-free survival |
| ROBUST (NCT02285062) | Lenalidomide+R-CHOP vs placebo+R-CHOP for first-line DLBCL | IMiD | PFS |
| B-MIND (NCT02763319) | BR vs MOR208 (tafasitamab-cxix)+bendamustine for R/R DLBCL | mAb | PFS |
| NCT01974440 | Ibrutinib+BR or R-CHOP vs placebo+BR or R-CHOP for R/R indolent NHL | mAb and BTKi | PFS |
| NCT04002297 | Zanubrutinib+rituximab vs BR for first-line MCL | mAb and BTKi | PFS |
| NCT04212013 | Ibrutinib+rituximab vs Ibrutinib+placebo | mAb and BTKi | CR rate |
| CHRONOS-3 (NCT02367040) | Copanlisib+rituximab vs placebo for R/R B cell NHL | mAb and PI3Ki | PFS |
| CHRONOS-4 (NCT02626455) | Copanlisib+rituximab-chemotherapy vs placebo+rituximab-chemotherapy for R/R indolent NHL | mAb and PI3Ki | Rate of dose-limiting toxicities/AEs, PFS |
| UNITY-NHL (NCT02793583) | TGR-1202+ublituximab vs TGR-1202 vs TGR-1202+ublituximab+bendamustine for R/R NHL | mAb and PI3Ki | ORR |
| NCT02320292 | Rituximab+IT vs rituximab for first-line FL | Radioimmunotherapy | CR rate |
ADC, antibody-drug conjugate; AEs, adverse events; AutoSCT, autologous stem cell transplant; BR, bendamustine, rituximab; BTKi, Bruton’s tyrosine kinase inhibitor; CAR, chimeric antigen receptor; CR, complete response; DA-R-EPOCH, dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; DLBCL, diffuse large B cell lymphoma; EFS, event-free survival; FL, follicular lymphoma; ICI, immune checkpoint inhibitor; IMiD, immunomodulatory drug; mAb, monoclonal antibody; MCL, mantle cell lymphoma; NHL, non-Hodgkin lymphoma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PI3Ki, phosphoinositide 3-kinase inhibitor; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHP, rituximab, cyclophosphamide, doxorubicin, prednisone; R-GemOx, rituximab, gemcitabine, oxaliplatin; R/R, relapsed or refractory; SOC, standard of care.